A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia

详细信息    查看全文

• 作者：Kotaro Miyao ; Masashi Sawa ; Mio Kurata…
• 关键词：Febrile neutropenia ; Liposomal amphotericin B ; Empirical therapy ; Antifungal therapy ; Hematological malignancy
• 刊名：International Journal of Hematology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：105
• 期：1
• 页码：79-86
• 全文大小：
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774
• 卷排序：105

文摘

Invasive fungal infection (IFI) is a major life-threatening problem encountered by patients with hematological malignancies receiving intensive chemotherapy. Empirical antifungal agents are therefore important. Despite the availability of antifungal agents for such situations, the optimal agents and administration methods remain unclear. We conducted a prospective phase 2 study of empirical 1 mg/kg/day liposomal amphotericin B (L-AMB) in 80 patients receiving intensive chemotherapy for hematological malignancies. All enrolled patients were high-risk and had recurrent prolonged febrile neutropenia despite having received broad-spectrum antibacterial therapy for at least 72 hours. Fifty-three patients (66.3 %) achieved the primary endpoint of successful treatment, thus exceeding the predefined threshold success rate. No patients developed IFI. The treatment completion rate was 73.8 %, and only two cases ceased treatment because of adverse events. The most frequent events were reversible electrolyte abnormalities. We consider low-dose L-AMB to provide comparable efficacy and improved safety and cost-effectiveness when compared with other empirical antifungal therapies. Additional large-scale randomized studies are needed to determine the clinical usefulness of L-AMB relative to other empirical antifungal therapies.